C76/100
Graded #9Editorial review
Henry Meds
A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.
Visit Henry Meds ↗Editorial review — no commercial relationship.
- Semaglutide
- $249/mo
- Tirzepatide
- $349/mo
- Coverage
- Multi-state
- Brand-name
- Compounded only
Factor breakdown
Each of the six graded dimensions. See the methodology.
Cost value72/100
Dose & formulation80/100
Clinical oversight80/100
Labs & monitoring78/100
Fulfillment78/100
Contract terms78/100
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Bottom line — Grade C
Best for: People who want a simple, well-known flat-fee program.
Pricing/verification reflect Henry Meds's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Henry Meds's site. Not medical advice; see our disclosure.